Cipla to further invest Rs. 42 crore in GoApptiv
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expands patient reach to remotest towns by furthering investment in GoApptiv
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Leading USA based genetic testing brand officially enters the Indian market
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated